Alka-372-001: First-in-human, phase I study of entrectinib - an oral pan-trk, ROS1, and ALK inhibitor - in patients with advanced solid tumors with relevant molecular alterations.

被引：28

作者：

De Braud, Filippo G.

Niger, Monica

Damian, Silvia

Bardazza, Benedetta

Martinetti, Antonia

Pelosi, Giuseppe

Marrapese, Giovanna

Palmeri, Laura

Cerea, Giulio

Valtorta, Emanuele

Veronese, Silvio

Sartore-Bianchi, Andrea

Ardini, Elena

Isachi, Antonella

Martignoni, Marcella

Galvani, Arturo

Luo, David

Yeh, Litain

Senderowicz, Adrian Mario

Siena, Salvatore

机构：

[1] Fdn IRCCS Ist Nazl Tumori, Milan, Italy

[2] Fdn IRCCS Ist Nazl Tumori, Med Oncol Unit, Milan, Italy

[3] Osped Niguarda Ca Granda, Niguarda Canc Ctr, Milan, Italy

[4] Nerviano Med Sci, Nerviano, Italy

[5] Nerviano Med Sci, Milan, Italy

[6] CLIn Org Strategies & Solut CLIOSS, NMS Grp, Nerviano, Italy

[7] Ignyta Inc, San Diego, CA USA

[8] Ignyta, San Diego, CA USA

[9] IGNYTA Inc, Somerville, MA USA

来源：

关键词：

D O I：

10.1200/jco.2015.33.15_suppl.2517

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2517

引用

页数：1